These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 31033793)
1. Characteristics and Survival Outcomes of Children With Hodgkin Lymphoma Treated Primarily With Chemotherapy. Ashraf MS; Naz F; Yakoob MY J Pediatr Hematol Oncol; 2019 Aug; 41(6):452-456. PubMed ID: 31033793 [TBL] [Abstract][Full Text] [Related]
2. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. Parambil BC; Narula G; Prasad M; Shah S; Shet T; Shridhar E; Khanna N; Laskar S; Gujral S; Sankaran H; Banavali S Pediatr Blood Cancer; 2020 Feb; 67(2):e28058. PubMed ID: 31724304 [TBL] [Abstract][Full Text] [Related]
3. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861 [TBL] [Abstract][Full Text] [Related]
4. ABVD or BEACOPP Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ; Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705 [TBL] [Abstract][Full Text] [Related]
6. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440 [TBL] [Abstract][Full Text] [Related]
7. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060 [TBL] [Abstract][Full Text] [Related]
8. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946 [TBL] [Abstract][Full Text] [Related]
9. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310 [TBL] [Abstract][Full Text] [Related]
10. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA; Voss SD; Friedman DL Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786406 [TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: First report by the South African Children's Cancer Study Group. Geel JA; Chirwa TC; Rowe B; Eyal KC; Omar F; Stones DK; Goga Y; Stefan DC; van Zyl A; Van Emmenes B; Wedi O; Vaithilingum M; Hendricks MG; Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28383768 [TBL] [Abstract][Full Text] [Related]
12. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. Ozuah NW; Marcus KJ; LaCasce AS; Billett AL J Pediatr Hematol Oncol; 2018 Aug; 40(6):e338-e342. PubMed ID: 29293187 [TBL] [Abstract][Full Text] [Related]
13. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy. Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084 [TBL] [Abstract][Full Text] [Related]
14. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study. Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162 [TBL] [Abstract][Full Text] [Related]
15. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. van den Berg H; Stuve W; Behrendt H Med Pediatr Oncol; 1997 Jul; 29(1):23-7. PubMed ID: 9142201 [TBL] [Abstract][Full Text] [Related]
17. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118 [TBL] [Abstract][Full Text] [Related]
18. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542 [TBL] [Abstract][Full Text] [Related]
19. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
20. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P; Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]